Skip to content

Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)

A Randomized Multicenter, Open, Prospective, Controlled Study-comparison of the Safety of Immediate One-stage Implant Based Breast Reconstruction(IBBR) Versus Two-stage Expander-Implant IBBR Augmented With TiLoop® Bra.

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03589924
Acronym
IBBR
Enrollment
440
Registered
2018-07-18
Start date
2018-06-01
Completion date
2024-09-30
Last updated
2024-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Immediate implant reconstruction, TiLoop® Bra

Brief summary

This study is the first prospective randomized study assessing the safety and patient-reported outcomes of immediate one-stage IBBR compared with those of two-stage IBBR with TiLoop® Bra.

Detailed description

Studies comparing two-stage implant-based breast reconstruction with immediate one-stage implant-based breast reconstruction have inconsistent results and investigators find that there is a lack of high quality evidence focusing on comparing one-stage and two-stage implant-based breast reconstruction with TiLoop®Bra. This study is the first prospective randomized study assessing the safety and patient-reported outcomes of immediate one-stage IBBR compared with those of two-stage IBBR with TiLoop® Bra in breast cancer patients. The hypothesis is that one step method is not inferior to two step method in implant based breast reconstruction following skin-sparing and/or Nipple-sparing mastectomy using TiLoop® Bra. The current study is a randomized multicenter, open labeled, prospective, controlled study. Participants were enrolled at six hospitals in different places of China. All participants will undergo Skin Sparing Mastectomy(SSM)/Nipple Sparing Mastectomy(NSM) with one-stage or two stage IBBR with TiLoop® Bra. Based on earlier experience, investigators calculated that the surgical complication rate was approximately 30 percent in the one-stage group and 25 percent in the two-stage group. Consider a dropout rate of 5%, a total of 450 patients, with 225 in each group, are needed.

Interventions

PROCEDUREImmediate IBBR+TiLoop®Bra

Patients will receive immediate implant reconstruction following mastectomy using TiLoop®Bra

PROCEDUREImmediate-delayed IBBR+TiLoop®Bra

Patients will receive immediate-delayed implant reconstruction following mastectomy using TiLoop®Bra

Sponsors

First Hospital of China Medical University
CollaboratorOTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
CollaboratorOTHER
The First Affiliated Hospital with Nanjing Medical University
CollaboratorOTHER
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
CollaboratorOTHER
Jiong Wu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All patients will undergo Skin Sparing Mastectomy(SSM)/Nipple Sparing Mastectomy(NSM) with one-stage or two stage IBBR with TiLoop® Bra.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with histological proven invasive breast cancer or ductal carcinoma in situ; * Clinical T1-T2 disease with no distant metastasis; * Patient with clinical N0 status; * Intent to receive NSM or SSM and implant based breast reconstruction; * Signed consent to participate.

Exclusion criteria

* Patient with severe breast ptosis; * Patient received ipsilateral breast reduction or enlargement; * Locally advanced stage patients who received neoadjuvant chemotherapy or hormone therapy; * Patients enrolled in other clinical trial which may as influence the outcome; * Patients received neo-adjuvant therapy and will receive radiotherapy. * History of breast cancer (ipsilateral, i.e. recurrence, or contralateral breast); * Patients of pregnancy or lactation.

Design outcomes

Primary

MeasureTime frameDescription
Rate of perioperative complicationsStart of randomization until 3 months after surgeryThe rate of perioperative complication between the two groups

Secondary

MeasureTime frameDescription
Additional surgery18 months after surgeryThe type of additional surgery following breast reconstruction
Quality of life:EORTC QLQ C30 /+ BR23 questionnaire18 months after surgeryEORTC QLQ C30 /+ BR23(EORTC breast cancer-specific quality of life) questionnaire to evaluate quality of life. Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including not at all for 1 score,a little for 2 score, quit a bit for 3 score and very much for 4 score. A higher score indicated a worse quality of life.
Patient satisfaction:Breast-Q questionnaire18 months after surgeryBreast-Q questionnaire to evaluate patients' satisfaction Using the reconstruction module of BREAST-Q to evaluate patient-reported outcome (PRO) of the surgery.For each subtheme, one or more BREAST-Q scales were developed to examine specific aspects of patient satisfaction. Patient responses to each scale's items are transformed through the Q-Score scoring software to provide a total scale score that ranges from 0 to 100. For all BREAST-Q scales, a higher score means greater satisfaction.
Aesthetic score of reconstructed breast18 months after surgeryHarris evaluation system to evaluate patients' breast aesthetic after surgery. Harris evaluation system is a 4-staged subjective evaluation method scored as excellent, good, fair, poor .
Angiopathology-related assessment of Tiloop bra18 months after surgeryThe angiopathology-related assessment in immediate-delayed reconstruction group

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026